The Wallace H. Coulter Foundation provides an operational roadmap to accelerate and fund the translation of technological innovations that improve patient care – research directed at the transfer of promising technologies from the university research laboratory to commercial development and clinical practice.

The UW Coulter TRP Program staff and your C4C technology manager will review your application and provide competitive landscape, end user inputs, specific market dynamics and an intellectual property review. Your application will be provided to the Center for Commercialization (C4C) for intellectual property assessment and initial assignment to an entrepreneur-in-residence (EIR). As appropriate, outside consultants are also engaged in due diligence on projects. The Coulter Oversight Committee makes final decisions on awards based on the full proposal, oral presentation, and diligence documents.

Applicant hereby consents to this process and agrees to be reasonably available to Coulter staff and C4C to answer any questions that may arise in this process.

APPLICATION PROCESS

Pre-proposals will be accepted November 3, 2014 through 5:00pm on January 9, 2015. Full proposal invitees will be announced by January 23, 2015 and full proposals will be due on or before 5:00pm on March 13, 2015. Oral presentations will be held in late April or early May 2015. The awards will be announced mid-May 2015 and funding will begin by June 1, 2015.

1. Pre-Proposal – Due on or before Friday, January 9, 2015 at 5:00pm

   Step 1. Prior to submission of the pre-proposal, PIs are required to meet with the Coulter Program Director, Kathie Jordan (kjordan@uw.edu), and their C4C technology manager (if assigned) to discuss project potential and the application process.

   Step 2: Pre-Proposal – A two (2) page pre-proposal is required prior to a full proposal application. The following information must be included in this document:

   - Project title, PI names and affiliations
   - Define the unmet clinical need you are solving, target population, and number of patients affected
   - Describe the product solution you envision to solve the problem, including a brief description of any preliminary data
Identify specific criteria that will prove your solution is better than the current “Gold Standard”

Describe the experimental timeline and steps to move your product into “first in human status” testing

**Step 3.** All pre-proposals must be submitted via email to the Coulter Program Director, Kathie Jordan (kjordan@uw.edu), and Assistant Director, Kassandra Thomson (coulter1@uw.edu). We also suggest that you send proposals to your C4C technology manager.

**II. Boot Camp for Non-dilutive Funding**

The UW Coulter TRP Program, in conjunction with the UW C4C, Institute for Neuroengineering, and Institute for Protein Design, will be offering a series of hands-on, interactive workshops in January-March 2015 designed to guide faculty and post-docs through the critical elements of non-dilutive commercialization funding grants. We strongly encourage every team to send at least one team member to the series of workshops. Detailed information will be available in January 2015.

**III. Full Proposal Application (by invitation) – Due on or before Friday, March 13, 2015 at 5:00pm**

**Part A:** The full proposal is limited to 6 pages total (Word) and must contain the following information:

- Project title, PI names and affiliations
- An explanation of clinical relevancy (clinical need, target population/market, product solution)
- An explanation and/or chart comparing 5 key proposed product attributes (ease of use, cost, etc.) to the current “Gold Standard” of practice
- A detailed translational research plan including experiments, milestones and timelines
- A pipeline chart explaining how commercialization might be achieved
- A description of how follow-on funding might be achieved after award funding expires
- No more than 1 page of reference publications

**Part B:** Applicants must also submit a separate Gantt chart (Excel) and a proposed budget (Word) – these are not included in the 6 page limit.

All full proposal applications must be submitted via email to the Coulter Program Director, Kathie Jordan (kjordan@uw.edu), and Assistant Director, Kassandra Thomson (coulter1@uw.edu). Full applications for the Coulter Translational Research Awards will be accepted once per year.

**ELIGIBILITY**

The UW Coulter TRP Program invites applications from principal investigators (PIs) who meet the following eligibility criteria:

- Projects must involve an active collaboration between a UW faculty member and a clinician. The clinician does not have to have an appointment at UW.
- Only one full proposal application per year per investigator. We will occasionally make exceptions to this policy with prior approval from the Coulter Program Director.
- Submission of a Report of Invention (ROI) filed at C4C.
EVALUATION CRITERIA

The UW Coulter TRP Program will review all applications for compliance with the eligibility criteria. A committee composed of experts in biomedical engineering, clinical practice, technology transfer, venture capital and business management will review the applications for funding. Each eligible application will be judged on the following criteria:

- Significant unmet or underserved clinical need
- Intellectual property position
- Substantial improvement over the “Gold Standard” of current care and/or a significant reduction in the cost of health care delivery
- Reasonable and achievable milestones
- High probability of attracting follow-on funding within 3-5 years of receiving the award
- Strength and nature of the clinical collaboration

In addition to a renewable grant of $100K, Coulter funded projects leverage resources from the UW Foster School of Business, UW School of Law, UW Center for Commercialization, local entrepreneurs, and business and industry experts.

CLINICAL COLLABORATORS

Because of the nature of the research supported by this award, collaboration between the Research PI and a clinical investigator affiliated with a clinical environment is required. Practicing clinicians often bring a sense of urgency, relevancy, and practicality to a biomedical research project that enhances the translational process. The collaboration may take a number of different forms, including the clinical investigator being a co-investigator in the research or a consultant to the project, but in any event, he/she must be involved in a substantive capacity and will be considered the co-PI.

HUMAN AND ANIMAL STUDIES

If the supported research involves the use of animal or human subjects, this should be indicated in the application submission and the appropriate institutional approvals must be obtained prior to the use of said animal or human subjects.

ADMINISTRATIVE GUIDELINES

ACCOUNTING

All funds advanced by The Coulter Foundation shall be used solely for the project described in this application and in accordance with the budget approved with the application. Over-expenditures in any budget cannot be covered.

ALLOWABLE BUDGET ITEMS

- A full Coulter award is approximately $100,000 for one year
- Expenditures may include salary and fringe benefits for project personnel, materials and supplies, and travel
• **Funds cannot be used for tuition, construction, or renovation**
• **No indirect cost can be charged for this award**

**OPERATING REVIEWS**

All Coulter Award recipients will be required to attend a mid-year operating review. The mid-year review will consist of an oral presentation and question and answer period with the Coulter Oversight Committee midway through the funding cycle (usually early December). Both PIs are required to participate in person or by conference call. In addition, if a business advisor is retained for your project, he/she must also attend.

**TRAVEL**

Awardees may be asked to attend the Coulter Foundation Annual Conference and possibly a trade show to present your product. Your travel cost will be covered by the Coulter Program.

**ADDITIONAL GUIDELINES**

**INTELLECTUAL PROPERTY POLICY**

The Wallace H. Coulter Foundation (WHCF) supports translational research – research that often involves discoveries or inventions that constitute intellectual property in the form of patents, copyrights, or trade secrets. It is the desire of WHCF that such intellectual property be administered in a manner that promotes commercialization and clinical use at the earliest possible time.

Except as provided hereafter, the entire right, title and interest to any invention or discovery, which is or may be patentable under the laws of the United States or any foreign country, and which is conceived or first actually reduced to practice in the course of performance under a grant from WHCF, shall be assigned to and retained by the University of Washington, unless the University is proscribed from doing so by Federal laws or regulations. If the University decides not to patent or otherwise develop the invention or discovery, the inventor(s) shall be free to patent or otherwise develop the invention subject to any rights that the University may retain under its patent policy.

WHCF waives any ownership rights in the patent, or the right to an exclusive or nonexclusive license to practice or assign the invention or discovery. The granting of an exclusive or nonexclusive license by the institution to practice the invention shall be in accordance with the institution’s policy on licensing.

In order to protect patent rights or trade secrets, publication or other public disclosure of information about the discovery or invention may be withheld for a reasonable period of time in accordance with the institution’s patent policy.

Institutions are expected to have formal safeguards in place for maintaining the highest ethical standards when faced with real or potential conflicts of interest relating to commercialization of discoveries or inventions developed in the course of a research project funded by WHCF. If the principal investigator(s) or any other person being supported under a grant from WHCF, has an arrangement with any organization (nonprofit or for-profit), other than the institution receiving the WHCF grant or the government, that would affect patent rights, trade secrets or copyrights for inventions or discoveries arising in whole or in part from the research supported by WHCF, information concerning such an arrangement shall be disclosed in writing at the time of the grant application or at the time such arrangements are agreed upon. In addition, if the principal investigator(s) or any other person being supported under a research grant from the WHCF has any ownership interest in a business
that could benefit from the research, or is an employee of such a business, this fact must also be disclosed in
the application or as soon as the ownership or employment relationship arises.

PRINCIPAL INVESTIGATOR RESIGNATIONS AND TRANSFERS
In the event of the PI’s resignation or inability to continue the project, the awardee should contact the UW
Coulter Program office, which will evaluate the specific circumstances to determine the disposition of funds. If
a PI transfers to another institution he/she is required to contact the UW Coulter Program, which will evaluate
the specific circumstances to determine if the Award is transferable.

PRIVACY POLICY

Information provided in your Coulter Translational Research Award application will be used to make a decision
as to whether or not to fund your research. As part of this decision making process, the UW Coulter Program
relies on outside advisors to assist in the review of all applications received and will use reasonable efforts to
not distribute your application beyond the parties described above.